On July 21, 2022 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, reported that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022 (Press release, Arbutus Biopharma, JUL 21, 2022, View Source [SID1234616832]). The schedule for the press release and conference call/webcast are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

•Q2/2022 Press Release: Thursday, August 4, 2022 at 7:30 a.m. ET
•Q2/2022 Conference Call/Webcast: Thursday, August 4, 2022 at 8:45 a.m. ET
•Domestic Dial-In Number: (800) 715-9871
•International Dial-In Number: (646) 307-1963
•Conference ID Number: 5109143
A live webcast of the conference call can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (800) 770-2030 or (609) 800-9909, and reference conference ID: 5109143.